{"schema_version":"secwatch.filing_event.v1","accession":"0001390478-24-000005","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.027072+00:00","generated_at":"2026-06-04T05:56:45.596607+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SELLAS FY2023 net loss $37.3M; SLS009 shows 50% response rate in r/r AML","bullets":["Net loss $37.3M ($1.34/sh) vs. $41.3M ($2.13/sh) in 2022; R&D expense $24.0M.","Cash at Dec 31, 2023: $2.5M; subsequent $9M (Jan) and $20M (Mar 2024) raised.","Phase 2a SLS009 in r/r AML: 50% response at 30mg BIW optimal dose; 100% in biomarker patients.","Phase 3 REGAL (GPS) enrollment completed; IDMC meeting late April; interim analysis possible in 1H2024.","Phase 1b/2 SLS009 in PTCL top-line data expected 1H2024; first DLBCL combo patient dosed."],"urls":{"canonical":"https://secwatch.observer/filing/0001390478-24-000005","json":"https://secwatch.observer/filing/0001390478-24-000005.json","markdown":"https://secwatch.observer/filing/0001390478-24-000005.md","text":"https://secwatch.observer/filing/0001390478-24-000005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000139047824000005/0001390478-24-000005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000139047824000005/sls-20240328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:56:45.596607+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9e196e326f26e74b5f5e982fb582916b63f518e0","claim":"SELLAS Life Sciences Group, Inc. reported financial results for the year ended December 31, 2023.","evidence_excerpt":"On March 28, 2024, SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the year ended December 31, 2023 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1390478/000139047824000005/0001390478-24-000005-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}